Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BDKRB1 | P46663 | 16/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12012158 | 0.91 | MAPK1 (0.43) | MAPK1KMT2ABDKRB1PKM | |
| SCHEMBL11947907 | 0.88 | BDKRB1 (0.46) | MAPK1KMT2ABDKRB1 | |
| SCHEMBL12012175 | 0.88 | BDKRB1 (0.48) | BDKRB1 | |
| SCHEMBL3440406 | 0.87 | PKM (0.49) | MAPK1KMT2ABDKRB1PKM | |
| SCHEMBL3443096 | 0.87 | KEAP1 (0.49) | MAPK1KMT2ABDKRB1 | |
| SCHEMBL12012193 | 0.86 | ALDH1A1 (0.52) | MAPK1KMT2ABDKRB1PKMHTT | |
| SCHEMBL3440414 | 0.85 | BDKRB1 (0.46) | MAPK1KMT2ABDKRB1 | |
| SCHEMBL2236762 | 0.85 | MAPK1 (0.50) | MAPK1KMT2ABDKRB1PKMHTT | |
| SCHEMBL12010517 | 0.83 | PKM (0.51) | MAPK1KMT2ABDKRB1PKM | |
| SCHEMBL12012220 | 0.82 | BDKRB1 (0.47) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-8865702-B2 | B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865702-B2 | B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2284166-B1 | Arylsulfonamides with analgetic activity | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100197664-A1 | NOVEL B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197664-A1 | NOVEL B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009013299-A2 | NOVEL BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | MAPK1 3196/4885KMT2A 4086/4885BDKRB1 6/4885 |
| US-20100197664-A1 | NOVEL B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | MAPK1 538/4885KMT2A 4129/4885BDKRB1 1/4885 |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | MAPK1 625/4885KMT2A 1859/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.